PUBLISHER: Allied Market Research | PRODUCT CODE: 1566976
PUBLISHER: Allied Market Research | PRODUCT CODE: 1566976
Urokinase Market By Type (Urokinase Powder, Urokinase Solution) , By End User (Hospital, Clinics) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Urokinase Market
The urokinase market was valued at $1.8 billion in 2023 and is projected to reach $3.1 billion by 2033, growing at a CAGR of 5.7% from 2024 to 2033.
Urokinase is a clot-busting drug which helps the body produce substances necessary to dissolve blood clots. Chemically, urokinase is a serine protease and is also known as urokinase-type plasminogen activator (uPA). The compound was initially isolated from human urine and is present in blood & extracellular matrix of several tissues. The drug is injected intravenously and is strictly administered under medical supervision. The drug is used to treat several conditions such as pulmonary embolism, acute myocardial infarction, and deep vein thrombosis.
Increase in the prevalence of cardiovascular disorders owing to exponentially growing elderly population and significantly changing lifestyle is a major driver of the urokinase market. In addition, improvements in formulation and advancements in drug delivery systems are boosting the demand for urokinase as an efficient treatment solution. Expansion of the treatment horizon of urokinase is currently trending in the market, with the drug proving to be beneficial for the treatment of primary nephrotic syndrome and tuberculous pleurisy. The combined effect of the drug and antituberculous therapy is comparatively better for the treatment of tuberculous pleurisy, than the therapy alone. The integration of urokinase decreases residual pleural thickness, increases total pleural effusion, improves pulmonary function, and reduces pleural effusion absorption time. In primary nephrotic syndrome, urokinase prevents venous thromboembolism, coupled with minor bleeding events.
However, the risk of bleeding complications remains significant in various individuals, thereby restraining the growth of the urokinase market. Moreover, the predominant usage of alternatives, including latest anticoagulant therapies and tissue plasminogen activator (tPA), is presenting significant challenges for the market development. On the contrary, constant R&D efforts toward the refinement of formulations are presenting novel opportunities for market expansion as these improved formulations exhibit less side effects and enhance the patient compliance. For instance, a fresh precursor of urokinase, known as pro-urokinase, is under clinical trials currently. This inactive precursor ensures the involvement of its fibrin-specific physiologic properties during conversion into active urokinase that are known to enhance the efficacy of the drug.
Segment Review
The urokinase market is segmented into type, end user, and region. On the basis of type, the market is bifurcated into urokinase powder and urokinase solution. As per end user, it is divided into hospital and clinics. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of type, the urokinase solution segment dominated the market in 2023.
As per end user, the hospital segment was the highest shareholder in 2023.
Region wise, the market is witnessing rapid expansion in Asia-Pacific.
Competition Analysis
The leading players operating in the global urokinase market include NDpharm, Wanhua Biochem, Jiangxi Haoran Bio-Pharma, Jiangsu Aidea Pharmaceutical, Techpool, Microbic Biosystems Inc, Livzon Pharmaceutical Group Inc., Cadila Healthcare Limited, TAJ Pharmaceuticals Limited, and Microbix Biosystems Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Type
- Urokinase Powder
- Urokinase Solution
By End User
- Hospital
- Clinics
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players:
- NDpharm
- Wanhua Biochem
- Jiangxi Haoran Bio-Pharma
- Jiangsu Aidea Pharmaceutical
- Techpool
- Microbic Biosystems Inc
- Livzon Pharmaceutical Group Inc.
- Cadila Healthcare Limited
- TAJ Pharmaceuticals Limited
- Microbix Biosystems Inc
TABLE OF CONTENTS
CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
CHAPTER 4: UROKINASE MARKET, BY TYPE
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Type
- 4.2. Urokinase Powder
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Urokinase Solution
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
CHAPTER 5: UROKINASE MARKET, BY END USER
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By End User
- 5.2. Hospital
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Clinics
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
CHAPTER 6: UROKINASE MARKET, BY REGION
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Region
- 6.2. North America
- 6.2.1. Key Market Trends and Opportunities
- 6.2.2. Market Size and Forecast, By Type
- 6.2.3. Market Size and Forecast, By End User
- 6.2.4. Market Size and Forecast, By Country
- 6.2.5. U.S. Urokinase Market
- 6.2.5.1. Market Size and Forecast, By Type
- 6.2.5.2. Market Size and Forecast, By End User
- 6.2.6. Canada Urokinase Market
- 6.2.6.1. Market Size and Forecast, By Type
- 6.2.6.2. Market Size and Forecast, By End User
- 6.2.7. Mexico Urokinase Market
- 6.2.7.1. Market Size and Forecast, By Type
- 6.2.7.2. Market Size and Forecast, By End User
- 6.3. Europe
- 6.3.1. Key Market Trends and Opportunities
- 6.3.2. Market Size and Forecast, By Type
- 6.3.3. Market Size and Forecast, By End User
- 6.3.4. Market Size and Forecast, By Country
- 6.3.5. Germany Urokinase Market
- 6.3.5.1. Market Size and Forecast, By Type
- 6.3.5.2. Market Size and Forecast, By End User
- 6.3.6. France Urokinase Market
- 6.3.6.1. Market Size and Forecast, By Type
- 6.3.6.2. Market Size and Forecast, By End User
- 6.3.7. UK Urokinase Market
- 6.3.7.1. Market Size and Forecast, By Type
- 6.3.7.2. Market Size and Forecast, By End User
- 6.3.8. Italy Urokinase Market
- 6.3.8.1. Market Size and Forecast, By Type
- 6.3.8.2. Market Size and Forecast, By End User
- 6.3.9. Spain Urokinase Market
- 6.3.9.1. Market Size and Forecast, By Type
- 6.3.9.2. Market Size and Forecast, By End User
- 6.3.10. Rest of Europe Urokinase Market
- 6.3.10.1. Market Size and Forecast, By Type
- 6.3.10.2. Market Size and Forecast, By End User
- 6.4. Asia-Pacific
- 6.4.1. Key Market Trends and Opportunities
- 6.4.2. Market Size and Forecast, By Type
- 6.4.3. Market Size and Forecast, By End User
- 6.4.4. Market Size and Forecast, By Country
- 6.4.5. Japan Urokinase Market
- 6.4.5.1. Market Size and Forecast, By Type
- 6.4.5.2. Market Size and Forecast, By End User
- 6.4.6. China Urokinase Market
- 6.4.6.1. Market Size and Forecast, By Type
- 6.4.6.2. Market Size and Forecast, By End User
- 6.4.7. Australia Urokinase Market
- 6.4.7.1. Market Size and Forecast, By Type
- 6.4.7.2. Market Size and Forecast, By End User
- 6.4.8. India Urokinase Market
- 6.4.8.1. Market Size and Forecast, By Type
- 6.4.8.2. Market Size and Forecast, By End User
- 6.4.9. South Korea Urokinase Market
- 6.4.9.1. Market Size and Forecast, By Type
- 6.4.9.2. Market Size and Forecast, By End User
- 6.4.10. Rest of Asia-Pacific Urokinase Market
- 6.4.10.1. Market Size and Forecast, By Type
- 6.4.10.2. Market Size and Forecast, By End User
- 6.5. LAMEA
- 6.5.1. Key Market Trends and Opportunities
- 6.5.2. Market Size and Forecast, By Type
- 6.5.3. Market Size and Forecast, By End User
- 6.5.4. Market Size and Forecast, By Country
- 6.5.5. Brazil Urokinase Market
- 6.5.5.1. Market Size and Forecast, By Type
- 6.5.5.2. Market Size and Forecast, By End User
- 6.5.6. Saudi Arabia Urokinase Market
- 6.5.6.1. Market Size and Forecast, By Type
- 6.5.6.2. Market Size and Forecast, By End User
- 6.5.7. South Africa Urokinase Market
- 6.5.7.1. Market Size and Forecast, By Type
- 6.5.7.2. Market Size and Forecast, By End User
- 6.5.8. Rest of LAMEA Urokinase Market
- 6.5.8.1. Market Size and Forecast, By Type
- 6.5.8.2. Market Size and Forecast, By End User
CHAPTER 7: COMPETITIVE LANDSCAPE
- 7.1. Introduction
- 7.2. Top Winning Strategies
- 7.3. Product Mapping of Top 10 Player
- 7.4. Competitive Dashboard
- 7.5. Competitive Heatmap
- 7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
- 8.1. NDpharm
- 8.1.1. Company Overview
- 8.1.2. Key Executives
- 8.1.3. Company Snapshot
- 8.1.4. Operating Business Segments
- 8.1.5. Product Portfolio
- 8.1.6. Business Performance
- 8.1.7. Key Strategic Moves and Developments
- 8.2. Wanhua Biochem
- 8.2.1. Company Overview
- 8.2.2. Key Executives
- 8.2.3. Company Snapshot
- 8.2.4. Operating Business Segments
- 8.2.5. Product Portfolio
- 8.2.6. Business Performance
- 8.2.7. Key Strategic Moves and Developments
- 8.3. Jiangxi Haoran Bio-Pharma
- 8.3.1. Company Overview
- 8.3.2. Key Executives
- 8.3.3. Company Snapshot
- 8.3.4. Operating Business Segments
- 8.3.5. Product Portfolio
- 8.3.6. Business Performance
- 8.3.7. Key Strategic Moves and Developments
- 8.4. Jiangsu Aidea Pharmaceutical
- 8.4.1. Company Overview
- 8.4.2. Key Executives
- 8.4.3. Company Snapshot
- 8.4.4. Operating Business Segments
- 8.4.5. Product Portfolio
- 8.4.6. Business Performance
- 8.4.7. Key Strategic Moves and Developments
- 8.5. Techpool
- 8.5.1. Company Overview
- 8.5.2. Key Executives
- 8.5.3. Company Snapshot
- 8.5.4. Operating Business Segments
- 8.5.5. Product Portfolio
- 8.5.6. Business Performance
- 8.5.7. Key Strategic Moves and Developments
- 8.6. Microbic Biosystems Inc
- 8.6.1. Company Overview
- 8.6.2. Key Executives
- 8.6.3. Company Snapshot
- 8.6.4. Operating Business Segments
- 8.6.5. Product Portfolio
- 8.6.6. Business Performance
- 8.6.7. Key Strategic Moves and Developments
- 8.7. Livzon Pharmaceutical Group Inc.
- 8.7.1. Company Overview
- 8.7.2. Key Executives
- 8.7.3. Company Snapshot
- 8.7.4. Operating Business Segments
- 8.7.5. Product Portfolio
- 8.7.6. Business Performance
- 8.7.7. Key Strategic Moves and Developments
- 8.8. Cadila Healthcare Limited
- 8.8.1. Company Overview
- 8.8.2. Key Executives
- 8.8.3. Company Snapshot
- 8.8.4. Operating Business Segments
- 8.8.5. Product Portfolio
- 8.8.6. Business Performance
- 8.8.7. Key Strategic Moves and Developments
- 8.9. TAJ Pharmaceuticals Limited
- 8.9.1. Company Overview
- 8.9.2. Key Executives
- 8.9.3. Company Snapshot
- 8.9.4. Operating Business Segments
- 8.9.5. Product Portfolio
- 8.9.6. Business Performance
- 8.9.7. Key Strategic Moves and Developments
- 8.10. Microbix Biosystems Inc
- 8.10.1. Company Overview
- 8.10.2. Key Executives
- 8.10.3. Company Snapshot
- 8.10.4. Operating Business Segments
- 8.10.5. Product Portfolio
- 8.10.6. Business Performance
- 8.10.7. Key Strategic Moves and Developments
